Free Trial

Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson logo
$176.75 +2.59 (+1.49%)
As of 02:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
10
Buy
11

Based on 21 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 10 have given a hold rating, 9 have given a buy rating, and 2 have given a strong buy rating for JNJ.

Consensus Price Target

$177.87
0.63% Upside
According to the 21 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $177.87. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $152.00. The average price target represents a forecasted upside of 0.63% from the current price of $176.75.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Analyst Ratings Over Time

TypeCurrent Forecast
9/19/24 to 9/19/25
1 Month Ago
8/20/24 to 8/20/25
3 Months Ago
6/21/24 to 6/21/25
1 Year Ago
9/20/23 to 9/19/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
10 Hold rating(s)
9 Hold rating(s)
11 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$177.87$174.50$170.88$173.21
Forecasted Upside0.63% Upside-2.29% Downside14.07% Upside5.09% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyHold

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Johnson & Johnson Stock vs. The Competition

TypeJohnson & JohnsonMedical CompaniesS&P 500
Consensus Rating Score
2.62
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.07% Upside13,450.06% Upside10.81% Upside
News Sentiment Rating
Positive News

See Recent JNJ News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/16/2025JPMorgan Chase & Co.
2 of 5 stars
Boost TargetNeutral$185.00 ➝ $200.00+13.33%
8/21/2025Citigroup
3 of 5 stars
Joanne Wuensch
Joanne Wuensch
4 of 5 stars
Boost TargetBuy$185.00 ➝ $200.00+11.13%
7/23/2025Erste Group Bank
3 of 5 stars
 UpgradeHoldBuy
7/17/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight
7/17/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$165.00 ➝ $176.00+8.13%
7/17/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$181.00 ➝ $185.00+13.50%
7/17/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$180.00 ➝ $190.00+16.28%
7/17/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$164.00 ➝ $167.00+2.20%
7/17/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$161.00 ➝ $175.00+6.20%
7/17/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$171.00 ➝ $176.00+6.81%
5/13/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
5/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform$169.00 ➝ $153.00-0.57%
4/24/2025Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
4/16/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingMarket Perform
4/14/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$165.00 ➝ $162.00+5.42%
4/9/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$157.00 ➝ $172.00+15.25%
1/24/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
1/23/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetHold$170.00 ➝ $155.00+5.58%
1/23/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetEqual Weight$166.00 ➝ $152.00+4.55%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$190.00+25.12%
10/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$215.00 ➝ $215.00+30.70%
7/23/2024Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
7/23/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformNeutral$160.00 ➝ $150.00-2.75%
7/18/2024TD Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$195.00 ➝ $185.00+18.03%
7/18/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$195.00 ➝ $185.00+18.38%
4/18/2024HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$169.00 ➝ $170.00+17.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 02:03 PM ET.


Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 16, 2025. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • The current stock price is around $177, reflecting a stable performance in the market.
  • Johnson & Johnson has a strong history of dividend payments, with a recent quarterly dividend of $1.30, translating to an annualized dividend yield of 2.9%, which can provide a steady income stream for investors.
  • Recent earnings reports show that the company exceeded revenue expectations, with a reported revenue of $23.74 billion, indicating robust business performance and growth potential.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with a target price averaging around $176.29, suggesting potential for price appreciation.
  • Johnson & Johnson's diversified portfolio in healthcare, including innovative medicines and medical technology, positions it well for long-term growth in a stable industry.

Johnson & Johnson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Despite recent positive earnings, the stock has shown volatility, with a 52-week high of $181.16 and a low of $140.68, indicating potential risks in price fluctuations.
  • The company's debt-to-equity ratio is 0.50, which, while manageable, suggests that the company has a moderate level of debt that could impact financial flexibility.
  • Market conditions can affect the healthcare sector, and any regulatory changes or negative news could impact Johnson & Johnson's stock performance.
  • Competition in the healthcare industry is fierce, and Johnson & Johnson must continuously innovate to maintain its market position, which can be a challenge.
  • Recent analyst ratings show a mix of opinions, with some analysts maintaining a "Hold" rating, indicating uncertainty about the stock's short-term performance.

JNJ Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $177.87, with a high forecast of $215.00 and a low forecast of $152.00.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 10 hold ratings, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JNJ shares.

According to analysts, Johnson & Johnson's stock has a predicted upside of 0.63% based on their 12-month stock forecasts.

Over the previous 90 days, Johnson & Johnson's stock had 1 upgrade by analysts.

Johnson & Johnson has been rated by research analysts at Bank of America, Barclays, Citigroup, Erste Group Bank, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Royal Bank Of Canada, and UBS Group in the past 90 days.

Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating score for Johnson & Johnson is 2.62 while the average consensus rating score for "medical" companies is 2.78. Learn more on how JNJ compares to other companies.


This page (NYSE:JNJ) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners